Salicylate prevents hepatic oxidative stress activation caused by short-term elevation of free fatty acids in vivo.

It has been reported that high-dose salicylates, an IKKß inhibitor, may prevent FFAs-induced insulin resistance. In previous study, we found that in FFAs-induced insulin resistant rats, administration of salicylate was associated with a reduction of plasma malondialdehyde (MDA). In the present study, we investigated the effects of sodium salicylate on FFAs-induced insulin resistance and on oxidative stress in liver.